Danaher Corporation (DHR) SVP Daniel Raskas Sells 37,870 Shares
Danaher Corporation (NYSE:DHR) SVP Daniel Raskas sold 37,870 shares of Danaher Corporation stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Danaher Corporation (NYSE DHR) traded down $0.28 on Friday, reaching $93.30. 1,510,518 shares of the company were exchanged, compared to its average volume of 2,668,045. Danaher Corporation has a 52-week low of $76.27 and a 52-week high of $93.86. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $65,090.00, a PE ratio of 23.96, a PEG ratio of 2.22 and a beta of 1.02.
Danaher Corporation (NYSE:DHR) last issued its earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.05. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The company had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same period in the prior year, the business posted $0.87 earnings per share. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. analysts anticipate that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were given a $0.14 dividend. The ex-dividend date was Thursday, September 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. Danaher Corporation’s dividend payout ratio is presently 16.67%.
A number of research analysts have issued reports on the company. Wells Fargo & Company reiterated a “market perform” rating on shares of Danaher Corporation in a research note on Saturday, July 22nd. Cowen and Company reiterated a “buy” rating and set a $90.00 price objective on shares of Danaher Corporation in a research note on Wednesday, October 4th. Jefferies Group LLC reiterated a “buy” rating and set a $95.00 price objective on shares of Danaher Corporation in a research note on Friday, August 4th. BidaskClub lowered Danaher Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $95.00 target price (up previously from $86.00) on shares of Danaher Corporation in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Danaher Corporation currently has a consensus rating of “Buy” and an average price target of $93.31.
Large investors have recently bought and sold shares of the business. Alley Co LLC acquired a new position in shares of Danaher Corporation in the 1st quarter valued at about $2,173,000. AE Wealth Management LLC acquired a new position in shares of Danaher Corporation in the 1st quarter worth approximately $282,000. Burney Co. increased its position in shares of Danaher Corporation by 2.9% in the first quarter. Burney Co. now owns 21,365 shares of the conglomerate’s stock worth $1,827,000 after acquiring an additional 596 shares in the last quarter. Boston Private Wealth LLC increased its position in shares of Danaher Corporation by 0.7% in the first quarter. Boston Private Wealth LLC now owns 196,718 shares of the conglomerate’s stock worth $16,826,000 after acquiring an additional 1,400 shares in the last quarter. Finally, ClariVest Asset Management LLC purchased a new position in shares of Danaher Corporation in the first quarter worth approximately $157,000. 75.38% of the stock is currently owned by institutional investors.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.